Project Grant HT94252510185
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$2.2M
Federal Agency
Defense Health Agency
Awardee
Projenx Inc. (TJLMX6EDJ8W9)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The federal Project Grant award of $654,391 was provided by the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to Evotec International GMBH. This funding supports a proof of concept study for a molecular glue approach to treat Amyotrophic Lateral Sclerosis (ALS). The project, scheduled from April 2024 to March 2026, aims to develop innovative treatments for neurodegenerative diseases. Evotec International GMBH, a leading drug discovery and development...
This $2,905,936 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a 4-year pilot randomized clinical trial to assess early ventilation interventions for patients with amyotrophic lateral sclerosis (ALS). The award recipient, The Trustees of the University of Pennsylvania, will leverage its expertise as a renowned private research university and academic medical center to conduct this innovative clinical...
The Defense Health Agency awarded a $1,210,500 Project Grant to Mayo Clinic under the Military Medical Research and Development program (CFDA 12.420) to explore novel biomarkers for amyotrophic lateral sclerosis (ALS) using a multiomics approach. The award, effective April 1, 2025 through March 31, 2028, will support research involving immunoprofiling, extracellular vesicle analysis, and TDP-43 aggregation assays. This project aims to advance the understanding of ALS pathogenesis and identify...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420).
The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
This $798,272 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research at The Johns Hopkins University to test the use of WNT inhibitors as a therapeutic to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The grant, with a performance period from March 2025 to March 2027, will enable the university to conduct this innovative biomedical research study focused on developing new...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The Defense Health Agency awarded Thomas Jefferson University a $779,200 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct senotherapy research for amyotrophic lateral sclerosis (ALS) from April 1, 2023 through March 31, 2025. The grant will support basic, applied, and advanced biomedical research investigating medical solutions for ALS, consistent with the program's goals of transforming military and public health care through innovative...